Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 1,501–1,560 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…ed T cell expansion in pre-therapy patient samples treated with pembrolizumab. In mice bearing neddylation-deficient breast EO771 tumors, PD-…
…herapy, and 56.7% were stage IV at diagnosis. Patients received nivolumab (10%), pembrolizumab (70%), or ipilimumab/nivolumab combination…
…nically approved anti-CTLA-4 antibodies, such as ipilimumab and tremelimumab, target Tregs to exert anti-tumor effects. However, their use r…
…e target for nivolumab, in CRC (n=4), RCC (n=2) and CaBr (n=3), Nivolumab treatment induced increase in proportion of activated effector …
…lophosphamide without (Cohort A) and with (Cohort B) continuous rhIL-15 infusion. Correlative studies included spectral flow cytometry,…
…ts from a phase 2, multicenter, open-label study of neoadjuvant cemiplimab in patients with high-risk, resectable CSCC ( NCT04315701).Meth…
…tiplex imaging. bioRxiv. 2022.Ascierto PA, et al. Sequencing of ipilimumab plus nivolumab and encorafeni bPlus binimetinib for untreated B…
…ment protocol comprised a preconditioning regimen consisting of cyclophosphamide (20 mg/kg/day, intravenous infusion, administered from day -5 t…
…equentially on the same tissue in a single well. ICI treatment (αPD-1, αPD-L1 or αPD-1+αCTLA-4) was aligned with the anticipated clin…
…istence, and minimal residual disease (MRD) in clinical trials. DuoCAR20.19.22-D95 is an investigational autologous CAR T-cell therapy targeting C…
…tinal toxicity, which constrains dose escalation and efficacy.2 A2B395 is an allogeneic, logic-gated, EGFR-targeted, Tmod CAR T therap…
…usion. Patients received non-myeloablative lymphodepletion with cyclophosphamide and fludarabine, followed by infusion of TIL and high-dose inte…